New funding for Cerenion for further development of the C‑Trend technology

Oulu-based health technology company Cerenion has received significant funding from the EU Innovation Fund and the Centre for Economic Development, Transport and the Environment (ELY-keskus).
The company will use the funding of 321,000 euros to further develop their C‑Trend technology as part of the CereStation project. The purpose is to develop innovative monitoring tools that make EEG in acute healthcare easier and more accessible than ever before. The project lasts for a year, from June 2024 to June 2025. The funding is mainly used for an R&D project that brings C‑Trend to the next level.
Cerenion is one of the most innovative health companies in the Oulu region. The company is revolutionising brain monitoring in intensive care units with their innovative C‑Trend® technology. Cerenion’s commitment to excellence is evident in rigorous clinical evaluations and adherence to international standards. The C‑Trend® technology is CE-marked as a medical device in Europe, underscoring its safety and efficacy.
Cerenion enhances patient care through innovative solutions, which positions them among leaders in the global health tech sector.
Source: Cerenion